Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA studyWilliam J. Sandborn, Geert D’Haens, Anindita Banerjee et al.|Gut|2017Cited by 107
Anti-MAdCAM Antibody Increases ß7+ T Cells and CCR9 Gene Expression in the Peripheral Blood of Patients With Crohn’s DiseaseMina Hassan‐Zahraee, Kenneth E. Hung, Anindita Banerjee et al.|Journal of Crohn s and Colitis|2017Cited by 26
Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II StudyGeert D’Haens, William J. Sandborn, Walter Reinisch et al.|Inflammatory Bowel Diseases|2021Cited by 16
P037 LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) MONOCLONAL ANTIBODY SHP647 IN CROHN’S DISEASE: THE OPERA II STUDYGeert D’Haens, William J. Sandborn, Walter Reinisch et al.|Gastroenterology|2019Cited by 1
Long-Term Safety, Efficacy and Pharmacokinetics of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) Monoclonal Antibody SHP647 in Crohnʼs Disease: The OPERA II StudyGeert D’Haens, William J. Sandborn, Walter Reinisch et al.|The American Journal of Gastroenterology|2018Cited by 0